
Friday, March 02, 2018 12:17:36 PM
Gabors response ( from memory ) was. ..." approx 5% could be anywhere between 4% and 6% ."...but I think Granowitz is skilled enough in modeling to be pretty accurate given the data they have access to .
Re the trial . As I stated earlier in my reply to Tas.....IMHO US patients in R-IT , especially diabetics , have access to new drugs ..Jardiance for example ...that show CV significant risk reduction .
So imagine if you are a 65 yr old US diabetic with 2 stents enrolled in R-IT . After the trial is not stopped at Interim 2 , you meet with your Cardiologist who explains that he was now prescribing Jardiance to high risk diabetics like you.
He explains that the risk reduction is over 30% over a 3- 4 yr follow up ( from memory ) for patients like you.
So do you add Jardiance and try and stay in R-IT
Drop out of the trial so you can add Jardiance
Reject Jardiance and stay in R-IT even tho theres a 50% chance you getting the placebo.
If you add Jardiance and stay in R-IT , or drop out ...IMHO takes longer to hit the final event ...and thats what we are seeing
JMO
Kiwi
Volume: | 55,645 |
Day Range: | 10.31 - 11.00 |
Bid: | 10.28 |
Ask: | 10.99 |
Last Trade Time: | 4:05:14 PM EDT |
Total Trades: | 1,062 |
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2025 01:00:03 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/11/2025 10:00:07 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2025 09:01:21 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2025 11:30:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2025 11:35:08 AM
- Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change • GlobeNewswire Inc. • 04/09/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2025 11:25:08 AM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 04/07/2025 11:50:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2025 11:40:08 AM
- Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors • GlobeNewswire Inc. • 04/07/2025 11:30:00 AM
- Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist • GlobeNewswire Inc. • 03/31/2025 12:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/28/2025 08:45:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/28/2025 08:45:07 PM
- New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Car • GlobeNewswire Inc. • 03/19/2025 11:30:00 AM
- Form F-6 POS - Post-effective amendments for immediately effective filing • Edgar (US Regulatory) • 03/12/2025 11:46:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2025 11:05:07 AM
- Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program • GlobeNewswire Inc. • 03/12/2025 11:01:00 AM
FEATURED Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement • Apr 25, 2025 8:33 AM
UAV Corp. Successfully Completes Inflation Test of DART SA-70 Airship, Paving Way for Flight Readiness • UMAV • Apr 24, 2025 8:30 AM
InnerScope Hearing Technologies (OTC: INND) Announces the Grand Opening of OTCHealthMart.com • INND • Apr 24, 2025 8:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM